An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Signify Health Expands In-Home Diagnostic and Preventive Services Offering, Introduces Spirometry Test for Detecting COPD
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Signify Health (NYSE: SGFY) announces the expansion of its in-home Diagnostic and Preventive Services for Medicare Advantage and Medicaid members, targeting major chronic health conditions. This initiative enhances early detection and management of diseases such as COPD, colorectal cancer, and diabetes, ultimately aiming to improve health outcomes and reduce care costs. Notably, spirometry testing for COPD, a significant health issue, is now part of this service. Early diagnosis is emphasized as key to effective treatment and mortality reduction.
Positive
Expansion of in-home Diagnostic and Preventive Services to improve access to care for Medicare members.
Focus on early detection and management of chronic diseases may lead to better patient outcomes.
Inclusion of spirometry testing for COPD enhances service offerings in a critical health area.
Negative
None.
The expanded offering aims to increase access to screenings and preventive care to address leading causes of morbidity and mortality among Medicare members
DALLAS & NEW YORK--(BUSINESS WIRE)--
Signify Health(NYSE: SGFY), a leading healthcare platform that leverages advanced analytics, technology and nationwide healthcare networks to create and power value-based payment programs, today announced the expansion of its in-home Diagnostic and Preventive Services offering for Medicare Advantage and Medicaid plan members.
The offering supports the early detection, diagnosis, and management of some of the leading causes of morbidity and mortality among Medicare members, including chronic obstructive pulmonary disease (COPD), peripheral arterial disease, colorectal cancer, chronic kidney disease, diabetes, and low bone density. These diagnostic and preventive services are performed during the Signify Health In-Home Health Evaluation to deliver a comprehensive and convenient care experience to patients.
“Early diagnosis and management of chronic conditions are critical to achieving better health outcomes and reducing the total cost of care,” said Marc Rothman, M.D., the Chief Medical Officer of Signify Health. “At Signify, we are performing diagnostic tests in the home to reduce barriers to timely diagnosis and treatment decisions by individuals and their physicians.”
Signify Health’s newest Diagnostic and Preventive Services offering is spirometry testing to detect COPD, which it began offering in select geographies in 2022. COPD is the fourth leading cause of death in the United States. Despite the high prevalence of COPD, the CDC estimates that just 50 percent of people living with the disease have been diagnosed. There is no cure for COPD, but early diagnosis and treatment are critical to slow disease progression and reduce the risk of mortality.
“The damage COPD causes to the lungs is irreversible and incurable. However, too often COPD goes undiagnosed,” said Dr. Rothman. “Signify Health clinicians are able to provide a real-time diagnosis of COPD after a thorough assessment of a patient’s spirometry test results, medical history, and physical examination.”
Signify Health uses advanced analytics to identify health plan members with gaps in care and to connect them with the appropriate diagnostic and preventive health services. Delivering these services in the home reduces barriers to care by providing health plan members with convenient access to high-value care to improve health outcomes.
About Signify Health
Signify Health is a leading healthcare platform that leverages advanced analytics, technology, and nationwide healthcare provider networks to create and power value-based payment programs. Our mission is to build trusted relationships to make people healthier. Our solutions support value-based payment programs by aligning financial incentives around outcomes, providing tools to health plans and healthcare organizations designed to assess and manage risk and identify actionable opportunities for improved patient outcomes, coordination and cost-savings. Through our platform, we coordinate what we believe is a holistic suite of clinical, social, and behavioral services to address an individual’s healthcare needs and prevent adverse events that drive excess cost, all while shifting services towards the home.
What is the recent announcement by Signify Health regarding their services for Medicare Advantage members?
Signify Health has expanded its in-home Diagnostic and Preventive Services for Medicare Advantage and Medicaid members, focusing on early detection of chronic diseases.
How does Signify Health's expansion of services aim to impact patient care?
The expansion aims to improve early diagnosis and management of diseases, ultimately enhancing health outcomes and reducing total care costs for patients.
What specific services have been added to Signify Health's offerings?
The new offerings include spirometry testing to detect chronic obstructive pulmonary disease (COPD) among other services.
Why is early diagnosis of COPD important according to Signify Health?
Early diagnosis is crucial for slowing disease progression and reducing mortality risk, as most individuals with COPD remain undiagnosed.
